Navigation Links
Patients Say MPM Medical's Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs
Date:3/30/2009

IRVING, Texas, March 30 /PRNewswire-FirstCall/ -- Patients undergoing cancer treatment reported that using Regenecare hydrogel significantly reduced the pain and itching associated with the sometimes-severe skin rashes caused by anti-cancer drugs.

Conducted by the Western University of Health Sciences, the study substantiated the findings of nine previous clinical trials recognizing Regenecare for its pain-relieving and wound-healing benefits. Manufactured by MPM Medical, Inc., Regenecare is the only wound and pain management product of its kind on the market.

"Pain management is one of the most-significant issues facing healthcare today," said MPM President Paul Miller. "Many patients stop or forgo treatment because they cannot tolerate the itching and painful side effects often associated with these treatments. Regenecare is a unique hydrogel whose benefits are substantiated by science and validated by patients."

The six-week study followed 13 patients who were taking a class of anti-cancer drugs that, while effective, often produce a severe rash on a patient's face, neck, back and legs. If scratched, these rashes can become infected. Patients reported "significant reduction" of itching when using Regenecare, according to the study.

Researchers credit Regenecare's unparalleled pain relief and wound healing to its formulation of 2% lidocaine (for local pain management), marine collagen (to promote tissue formation), Aloe vera (to enhance circulation and to promote emollient effect) and sodium alginate (to absorb exudates).

"Pain is the leading cause of disability in the United States and is straining our healthcare system," according to the National Pain Care Policy Act of 2008 (H.R. 2994). Among other things, the pending legislation seeks "to improve the assessment, understanding and treatment of pain."

MPM offers Regenecare HA as an over-the-counter version of the prescription Regenecare. Regenecare HA has the same formulation, but it also contains hyaluronic acid, which enhances moisture and healing. Consumers may purchase Regenecare and other MPM products online at www.MPMmedicalinc.com.

About RBC Life SciencesRBC Life Sciences (OTC Bulletin Board: RBCL) develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical, Inc., brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE RBC Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DaVitas IMPACT Program Reduces Mortality for New Dialysis Patients
2. Hormone Reduces Mortality in Heart Patients With High BP
3. LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination
4. Patients Bill of Rights Too Tough to Read
5. Emmi + KidsHealth = Prescription for Informed and Involved Patients
6. Individualized stroke treatment available for patients, though underutilized
7. External focus improves postural stability in patients with Parkinsons disease
8. Northeast Ohio's Center for Orthopedics Saves Patients Time with Online Next-Day Appointment Scheduling for its Open Cast Room
9. TMA Physicians and Legislators: Patients Have a Right to Know
10. Music Can Help Restore Stroke Patients Sight
11. Drug Combo Helps Larynx Cancer Patients Preserve Voice Box
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... Only two months after the official release of The Private Collection ... XO Private has initiated a second print-run of its lavish luxury travel coffee table ... when open, weighs in at more than six kilos, retails at EUR 1,000 per ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology: